Used as an antimalarial agent, particularly in combination with dihydroartemisinin for the treatment of uncomplicated Plasmodium falciparum malaria. It is effective in regions with resistance to other antimalarial drugs due to its long half-life, which provides prolonged protection against reinfection. The combination therapy is recommended by the World Health Organization for artemisinin-based combination treatments (ACTs). Piperaquine phosphate is especially valuable in pediatric and mass drug administration settings because of its favorable safety profile and efficacy.